Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

Executive Summary

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

You may also be interested in...



Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline

AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab for cancer and benralizumab for asthma are among important milestones ahead.

AstraZeneca, Firing On All Cylinders, Sets Aggressive R&D Goals

The U.K. drug maker flaunted its dramatically improved pipeline to investors Nov. 18, highlighting oncology specifically, a new “growth platform.” But will investors be persuaded to wait three years for growth?

End Of An Era? AstraZeneca Closes India Research Site Focused On Tropical Diseases

Stakeholders are asking if AstraZeneca remains committed to neglected tropical diseases after the company announces it will close its Indian research unit. The center was the last remaining big pharma basic research center in India.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel